Literature DB >> 6296841

Opiates and classical conditioning: selective abolition of conditioned responses by activation of opiate receptors within the central nervous system.

M D Mauk, J Madden, J D Barchas, R F Thompson.   

Abstract

It has previously been shown that opiates produce selective abolition of aversively motivated classically conditioned responses in the rabbit. The experiments reported here show that these effects are mediated by specific activation of opiate receptors within the central nervous system in that this central activation is both necessary and sufficient to produce opiate-induced abolition of conditioned responding. Further characterization suggests that selective activation through opiate-mu-receptor interactions within the periaqueductal gray/periventricular region of the fourth ventricle may be critical in mediating this abolition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296841      PMCID: PMC347388          DOI: 10.1073/pnas.79.23.7598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Glucosyl Zeatin and Glucosyl Ribosylzeatin from Vinca rosea L. Crown Gall Tumor Tissue.

Authors:  J B Peterson; C O Miller
Journal:  Plant Physiol       Date:  1977-06       Impact factor: 8.340

2.  Neuronal substrate of classical conditioning in the hippocampus.

Authors:  T W Berger; B Alger; R F Thompson
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

3.  Vagal compensatory adjustment: relationship to heart rate classical conditioning in rabbits.

Authors:  N Schneiderman; D H Van Dercar; A L Yehle; A A Manning; T Golden; E Schneiderman
Journal:  J Comp Physiol Psychol       Date:  1969-06

4.  Divergences among rabbit response systems during three-tone classical discrimination conditioning.

Authors:  A L Yehle
Journal:  J Exp Psychol       Date:  1968-07

5.  Endorphins alter acquisition and consolidation of an inhibitory avoidance response in rats.

Authors:  J L Martinez; H Rigter
Journal:  Neurosci Lett       Date:  1980-09       Impact factor: 3.046

6.  Analgesic activity of intracerebroventricular administration of morphiceptin and beta-casomorphins: correlation with the morphine (micro) receptor binding affinity.

Authors:  K J Chang; P Cuatrecasas; E T Wei; J K Chang
Journal:  Life Sci       Date:  1982-05-03       Impact factor: 5.037

7.  Hippocampal unit-behavior correlations during classical conditioning.

Authors:  T W Berger; R I Laham; R F Thompson
Journal:  Brain Res       Date:  1980-07-07       Impact factor: 3.252

8.  Enkephalins interfere with acquisition of an active avoidance response.

Authors:  H Rigter; T J Hannan; R B Messing; J L Martinez; B J Vasquez; R A Jensen; J Veliquette; J L McGaugh
Journal:  Life Sci       Date:  1980-02-04       Impact factor: 5.037

9.  Cytoplasmic Male Sterility in Barley : VIII. LIPOXYGENASE ACTIVITY AND ANTHER AMINO NITROGEN IN THE msm1-Rfm1a SYSTEM.

Authors:  H Ahokas
Journal:  Plant Physiol       Date:  1982-01       Impact factor: 8.340

10.  Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): a potent and specific agonist for morphine (mu) receptors.

Authors:  K J Chang; A Lillian; E Hazum; P Cuatrecasas; J K Chang
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

View more
  3 in total

1.  Blockade of endogenous opioid neurotransmission enhances acquisition of conditioned fear in humans.

Authors:  Falk Eippert; Ulrike Bingel; Eszter Schoell; Juliana Yacubian; Christian Büchel
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

2.  Sensory and associative effects of morphine and naloxone in classical conditioning of the rabbit nictitating membrane response.

Authors:  C W Schindler; I Gormezano; J A Harvey
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 3.  Peptide neuroregulators: the opioid system as a model.

Authors:  J D Barchas; C Evans; G R Elliott; P A Berger
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.